Publications by authors named "Enrique Leal"
Article Synopsis
- The study aimed to determine if selecting oral antiplatelet drugs based on a patient's genotype using a clinical decision support algorithm can lower the rate of major adverse cardiovascular and cerebrovascular events among Caribbean Hispanic patients following treatment.
- Conducted as an open-label, multicenter, non-randomized trial across eight hospitals in Puerto Rico, it involved 300 patients who received percutaneous coronary intervention and were divided into standard-of-care and genotype-guided groups.
- Results indicated that although the genotype-guided group had a lower risk of major adverse events compared to the standard group (8.7% vs 10.7%), the difference was not statistically significant.
Background: After percutaneous coronary intervention (PCI), clopidogrel resistant patients are at an increased risk of major adverse cardiovascular and cerebrovascular events (MACCEs). We aimed to assess whether genotype-guided selection of oral antiplatelet drugs using a clinical decision support (CDS) algorithm reduces the occurrence of these ischemic events and improves outcomes among Caribbean Hispanic patients from Puerto Rico, who are underrepresented in clinical pharmacogenomic (PGx)-guided implementation studies.
Methods: Individual platelet function testing (PRU) measures, *2 and rs662 genotypes, clinical and demographic data from 8 medical facilities were included.
Cromoglycate (SCG) is widely used for allergy processes, and inflammatory states acting as a mast cell membrane stabilizer that inhibits the histamine and mediator release. Currently, SCG topical extemporaneous compounding formulations are prepared in hospitals and community pharmacies, as no industrial fabricated medicines are available in Spain. The stability of these formulations is unknown.
View Article and Find Full Text PDF